FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
21 letters match. Newest first.
-
DrugsRohto Pharmaceutical Co., Ltd.
FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.
High risk -
DrugsBoothwyn Pharmacy, LLC
Boothwyn Pharmacy made sterile drugs in insanitary conditions and shipped lots that failed sterility and potency tests.
High risk -
DrugsSupply Center USA
Supply Center USA offered unapproved Similasan and Boiron eye drug products for sale online.
High risk -
DrugsOasis Medical, Inc.
FDA cites Oasis Medical for current good manufacturing practice violations in sterile ophthalmic drugs, including particulate contamination and unresolved sterility failures.
High risk -
DrugsScope Health Inc
FDA says Scope Health sold unapproved OTC eye drugs online and misbranded several products.
High risk -
DrugsThea Pharma, Inc.
FDA warns Thea Pharma that IVIZIA OTC lubricant eye drops are an unapproved and misbranded new drug.
High risk -
DrugsAACE Pharmaceuticals, Inc.
AACE Pharmaceuticals distributed adulterated Lubricant PM Ointment made by CMO Brassica with CGMP violations and failed supplier qualification.
High risk -
DrugsOSRX, Inc.
OSRX, a Montana compounding facility, made sterile ophthalmic drugs under insanitary conditions with quality and labeling failures.
High risk -
DrugsAspen Pharmacare Holdings Limited
FDA warns Aspen subsidiary over sterile OTC drug manufacturing failures including impurity testing, aseptic practices, data integrity, and environmental monitoring.
High risk -
DrugsVelocity Pharma LLC
Velocity Pharma distributed eye drop drugs made by contract manufacturers with serious manufacturing and sanitation violations.
High risk -
DrugsOptikem International Inc.
FDA warns Optikem International after inspection found inadequate aseptic controls for sterile ophthalmic drugs, including contamination and validation failures.
High risk -
DrugsEzriCare LLC
EzriCare distributed non-sterile Artificial Tears made by a CMO with CGMP violations, linked to a Pseudomonas outbreak.
High risk -
DrugsSouthern Tier Home Infusion, Inc. dba Pharmacy Innovations
FDA warned compounding pharmacy Pharmacy Innovations that its sterile drugs were made under insanitary conditions and without valid patient prescriptions.
High risk -
DrugsDR Vitamins, LLC dba DR Vitamin Solutions
FDA warned DR Vitamin Solutions that its eye drops are unapproved new drugs and misbranded.
High risk -
DrugsCVS Health
FDA told CVS Health its unapproved Pink Eye Relief Drops are an illegal new drug made by a manufacturer with serious quality violations.
High risk -
DrugsTRP Company, Inc
FDA warns TRP Company that its homeopathic eye drops and ointments are unapproved new drugs and may be adulterated.
High risk -
DrugsSimilasan AG
Similasan AG's ophthalmic drugs are unapproved new drugs and violate CGMP (manufacturing quality rules), FDA says.
High risk -
DrugsK.C. Pharmaceuticals Inc.
FDA warned K.C. Pharmaceuticals after inspections found manufacturing rule violations in sterile ophthalmic drugs, including inadequate contamination controls and cleaning validation.
High risk -
DrugsImprimisRx NJ
FDA found insanitary sterile compounding and subpotent timolol-latanoprost eye drops at ImprimisRx NJ.
High risk -
DrugsSterling Pharmaceutical Services, LLC
Sterling Pharmaceutical Services, LLC made sterile ophthalmic drugs with manufacturing violations and marketed unapproved new drugs.
High risk -
DrugsImprimis Rx LLC
FDA warns Imprimis Rx over false, misleading promotion of compounded eye drug Pred-Moxi-Brom.
Low